Evidence map›Paper›PMID 39981760›Full record

SynthesisActa obstetricia et gynecologica Scandinavica2025

Association of oral contraceptives and risk of endometrial cancer: A systematic review and meta-analysis.

András Harajka, Tímea Hercsik, Isabel Pinto Amorim das Virgens, Izabella Máthé, Zsófia Tornyossy, Ali AlFarwi, Fanni Adél Meznerics, Szilvia Kiss-Dala, Péter Fehérvári, Rita Nagy and 5 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Acta obstetricia et gynecologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

András HarajkaCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0009-0000-3007-2564
Tímea HercsikCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Isabel Pinto Amorim das VirgensCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Izabella MáthéCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Zsófia TornyossyCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Ali AlFarwiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Fanni Adél MeznericsCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Szilvia Kiss-DalaCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Péter FehérváriCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Rita NagyCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Ferenc BánhidyCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Attila MajorosCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Sándor ValentCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Péter HegyiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Nándor ÁcsCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0002-1919-1869

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlthough the relationship between the use of oral contraceptives and reduced endometrial cancer risk has now long been established, the need for female patients to be informed on this matter based on the latest results of scientific research remains. To help the evidence-based decision-making of women when choosing contraception methods, we aimed to provide them with an up-to-date overview and summary of past and recent findings on the association between the use of oral contraceptives and endometrial cancer risk. MATERIAL AND

methodsThis study was registered in PROSPERO: CRD42022379871. PubMed, Embase, and Cochrane Library databases were searched on the December 5, 2022, to identify eligible articles. We included all experimental and observational studies that reported the number of users and non-users of oral contraceptives among patients diagnosed or not with endometrial cancer. Data were extracted, and random-effects meta-analysis was performed to obtain summary odds ratios (OR) with 95% confidence intervals (CI). Heterogeneity across studies was assessed using Higgins & Thompson's I

resultsFifty-six studies were eligible for qualitative synthesis, of which twenty-five were eligible for quantitative analysis. The use of oral contraceptives was inversely associated with the odds of having endometrial cancer (OR = 0.61, CI: 0.46-0.80). The long-term use of oral contraceptives led to the greatest odds reduction in having endometrial cancer (≥10 years: OR = 0.31, CI: 0.13-0.70), while shorter periods were also associated with a significant decrease in these odds, although to a lesser extent (≥5 years: OR = 0.39, CI: 0.23-0.64; <5 years: OR = 0.66, CI: 0.48-0.91).

conclusionsThe administration of oral contraceptives is time dependently associated with lower odds of having endometrial cancer, suggesting a protective association between the use of oral contraceptives and endometrial cancer.

Indexed as

Contraceptives, OralEndometrial NeoplasmsFemaleHumansRisk FactorsContraceptives, Oralbirth control pillendometrial cancerfamily planningmalignancyoral contraceptivestumoruterus

Identifiers

PMID39981760
PMCPMC11919752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.